Horsham, United Kingdom

Oliver Ross Steward

This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2017-2019.

USPTO Granted Patents = 2 


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017-2019

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Oliver Ross Steward: Innovator in Autotaxin Inhibitors

Introduction

Oliver Ross Steward is a notable inventor based in Horsham, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of autotaxin inhibitors. With a total of two patents to his name, Steward's work is recognized for its potential impact on various diseases and disorders.

Latest Patents

Steward's latest patents focus on novel compounds that act as autotaxin inhibitors. The inventions detail processes for their preparation, pharmaceutical compositions, and medicaments containing these compounds. These innovations aim to address diseases and disorders mediated by autotaxin, showcasing Steward's commitment to advancing medical science.

Career Highlights

Oliver Ross Steward is currently associated with Novartis AG, a leading global healthcare company. His role at Novartis allows him to collaborate with other experts in the field and contribute to groundbreaking research and development.

Collaborations

Steward has worked alongside notable colleagues such as David Beattie and Urs Baettig. Their combined expertise enhances the innovative efforts within their projects, fostering a collaborative environment that drives success.

Conclusion

Oliver Ross Steward is a distinguished inventor whose work on autotaxin inhibitors holds promise for the future of medicine. His contributions to Novartis AG and collaboration with esteemed colleagues further solidify his impact in the pharmaceutical industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…